Primary Endpoint

Key facts

Where it is recorded

Protocol, statistical analysis plan, ClinicalTrials.gov record

Results deadline (applicable trials)

Generally 1 year after the primary completion date, 42 CFR Part 11

Surrogate-based approval

Accelerated approval, 21 CFR 314.510 (drugs), 601.41 (biologics)

What is a primary endpoint?

Every confirmatory trial is built around one main question, and the primary endpoint is the measurement that answers it. Examples include overall survival in a cancer trial, change in HbA1c in a diabetes trial, or the rate of major cardiovascular events over a set follow-up period. The endpoint definition states what is measured, how, and at what time point.

Secondary endpoints capture additional effects, and exploratory endpoints generate hypotheses. A trial is generally judged on its primary endpoint, and secondary results are hard to interpret when the primary endpoint is missed, because testing many outcomes raises the chance of false positives.

Types of endpoints

Common endpoint types include:

• Clinical outcome endpoints: directly measure how a patient feels, functions or survives, such as death, stroke or hospitalization.
• Surrogate endpoints: laboratory measures or physical signs, such as blood pressure or tumor shrinkage, that stand in for clinical outcomes.
• Patient-reported outcomes: symptoms or function reported directly by participants on validated questionnaires.
• Composite endpoints: several events, such as death, heart attack or stroke, combined into one measure.

Why the primary endpoint matters

The primary endpoint shapes what a drug label can claim and how payers value the product. A drug approved on a surrogate endpoint under accelerated approval must confirm clinical benefit in later trials, and payers and health technology assessment bodies often weigh surrogate-based evidence cautiously. FDA publishes a table of surrogate endpoints that have supported approvals.

ClinicalTrials.gov records the primary outcome measure and its time frame. Results for applicable clinical trials are generally due within one year of the primary completion date, the date the last participant was examined or treated to collect final data for the primary outcome. Analysts use that date to estimate when topline results will appear, and compare registered endpoints with published ones to spot outcome switching.